Approach to the treatment-experienced patient.

[1]  J. Church.  Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients With Triple-Class Resistant Virus , 2007, Pediatrics.

[2]  Wei Huang,et al.  Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. , 2007, The Journal of infectious diseases.

[3]  Eoin Coakley,et al.  Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Rebecca Hoh,et al.  Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis , 2006, Journal of acquired immune deficiency syndromes.

[5]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[6]  P. Anderson,et al.  Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. , 2006, The Journal of antimicrobial chemotherapy.

[7]  V. Soriano,et al.  Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. , 2006, The Journal of antimicrobial chemotherapy.

[8]  Laura Galli,et al.  Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) , 2006, AIDS.

[9]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[10]  J. Chmiel,et al.  Transient viremia in HIV-infected patients and use of plasma preparation tubes. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Rebecca Hoh,et al.  Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.

[12]  D. Edwards,et al.  HIV-1 Drug Resistance Evolution Among Patients on Potent Combination Antiretroviral Therapy With Detectable Viremia , 2005, Journal of acquired immune deficiency syndromes.

[13]  B. Gazzard,et al.  British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005) , 2005, HIV medicine.

[14]  R. Haubrich,et al.  A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575 , 2005, AIDS.

[15]  Tara L. Kieffer,et al.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.

[16]  Steve A Castillo,et al.  Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Tara L. Kieffer,et al.  Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Neil Parkin,et al.  Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. , 2004, The Journal of infectious diseases.

[19]  R. Elston,et al.  GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks , 2004, AIDS.

[20]  Roland Tubiana,et al.  Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097) , 2004, AIDS.

[21]  R. Paredes,et al.  Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. , 2003, The Journal of infectious diseases.

[22]  Gary Collins,et al.  Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.

[23]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[24]  D. Havlir,et al.  Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia , 2002, Antimicrobial Agents and Chemotherapy.

[25]  Brian G Gazzard,et al.  The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml , 2002, AIDS.

[26]  R. Schooley,et al.  Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study , 2002, AIDS.

[27]  A. Sönnerborg,et al.  Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy , 2002, AIDS.

[28]  Robert W. Shafer,et al.  Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.

[29]  Pierre-Marie Girard,et al.  Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial , 2002, AIDS.

[30]  Michael Ames,et al.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy , 2002, AIDS.

[31]  A. Antinori,et al.  Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) , 2002, AIDS.

[32]  Lidia Ruiz,et al.  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial , 2002, AIDS.

[33]  M. Mouroux,et al.  Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.

[34]  Steve Kaye,et al.  Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance , 2001, Journal of acquired immune deficiency syndromes.

[35]  V. Soriano,et al.  Drug resistance in patients experiencing early virological failure under a triple combination including indinavir , 2001, AIDS.

[36]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[37]  R. Siliciano,et al.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.

[38]  M. Kazatchkine,et al.  Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. , 2001, The Journal of infectious diseases.

[39]  R. Haubrich,et al.  International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. , 2001, Journal of acquired immune deficiency syndromes.

[40]  R. D’Aquila,et al.  Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[42]  A. Mocroft,et al.  The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study , 2001, AIDS.

[43]  P. Harrigan,et al.  Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens , 2001, AIDS.

[44]  E. De Clercq,et al.  Prevalence of Genotypic Resistance among Antiretroviral Drug-Naive HIV-1-Infected Patients in Belgium , 2001, Antiviral therapy.

[45]  E. Rosenberg,et al.  Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Kazatchkine,et al.  Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[47]  M. Mouroux,et al.  Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir (Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring Viral Resistance , 2000, Journal of Clinical Microbiology.

[48]  Brendan A. Larder,et al.  Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.

[49]  T. Merigan,et al.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .

[50]  R. Harrigan,et al.  Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies , 2000, AIDS.

[51]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[52]  V. Calvez,et al.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.

[53]  K. Hertogs,et al.  HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort , 2000, Antiviral therapy.

[54]  S. Hammer,et al.  The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.

[55]  P. Harrigan,et al.  Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. , 1999, The Journal of infectious diseases.

[56]  W. Miller,et al.  Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. , 1999, AIDS.

[57]  M. Zazzi,et al.  Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. , 1999, Journal of acquired immune deficiency syndromes.

[58]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[59]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[60]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[61]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[62]  J. Leonard,et al.  The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir , 1998, AIDS.

[63]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[64]  D. Kuritzkes,et al.  Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .

[65]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[66]  A. Hsu,et al.  Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.

[67]  UvA-DARE (Digital Academic Repository) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia , 2022 .